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Summary
Choreoathetosis is a major clinical feature in only a small
number of hereditary neurological disorders. We define
a new X-linked syndrome with a unique clinical picture
characterized by mild mental retardation, choreoathe-
tosis, and abnormal behavior. We mapped the disease
in a four-generation pedigree to chromosome Xp11 by
linkage analysis and defined a candidate region contain-
ing a number of genes possibly involved in neuronal
signaling, including a potassium channel gene and a neu-
ronal G protein–coupled receptor.
Introduction
At least 178 conditions involving mental retardation
have been mapped to the X chromosome. These con-
ditions can be subdivided into syndromic and nonsyn-
dromic forms. In addition to mental retardation, 120
syndromes (53 mapped and 22 cloned) show a char-
acteristic pattern of biochemical, morphological, or neu-
rological manifestations. Fifty-eight nonspecific mental
retardation loci (only five cloned) show mental retar-
dation as the only characteristic (Lubs et al. 1999). In
this study we report on a family with an X-linked re-
cessive condition that combines mental retardation with
neurological symptoms. Five patients from this four-gen-
eration family show mild mental retardation in addition
to choreoathetosis and abnormal behavior.
Choreoathetosis, the most distinguishing feature of
these five patients, is characterized by involuntary, ir-
regular, purposeless, nonrhythmic, abrupt, rapid move-
ments flowing from one part of the body to another
(chorea) that blend with slow, writhing, continuous
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movements (athetosis). It occurs in a variety of clinically
and genetically diverse disorders, albeit rarely in familial
forms. Only three X-linked mental retardation syn-
dromes showing choreoathetoid movements—Lesch-
Nyhan syndrome (MIM 308000), Schimke X-linked
mental retardation syndrome (MIM 312840), and Pet-
tigrew syndrome (MRXS5; MIM 304340)—have been
described. Lesch-Nyhan syndrome is a rare recessive dis-
order of purine metabolism due to mutations in the hy-
poxanthine phosphoribosyl transferase gene (HPRT)
(Rossiter et al. 1991) and is characterized by hypercur-
icemia, spasticity, choreoathetosis, dystonia, self-injuri-
ous behavior, and aggression (Nyhan et al. 1967). Child-
hood-onset choreoathetosis combined with postnatal
microcephaly, growth and mental retardation, apparent
external ophthalmoplegia, and varying degrees of deaf-
ness characterize Schimke X-linked mental retardation
(Schimke et al. 1984). Manifestations of Pettigrew syn-
drome (Xq26) include severe mental retardation, early
hypotonia with progression to spasticity, choreoathe-
tosis, seizures, Dandy-Walker malformation, and iron
accumulation in the basal ganglia (Pettigrew et al. 1991).
The clinical symptoms of the patients in the family
studied do not seem compatible with any of these known
disorders. Although the patients have the choreoathetoid
movements in common in each of the three disorders,
Lesch-Nyhan syndrome and Schimke mental retardation
have, in addition, different clinical manifestations, such
as the presence of uric acid renal stones and spastic ce-
rebral palsy, and microcephaly and deafness, respec-
tively. Pettigrew syndrome is not likely the same syn-
drome, since patients in our family do not show
hypointense areas typical of iron accumulation in the
basal ganglia. Therefore, we hypothesized that, clini-
cally, the condition in this family is unique. We mapped
the disease to Xp11 and thus defined a new X-linked
syndrome.
Patients and Methods
Patients
A four-generation Luxembourg family, including five
male patients, was studied. The pedigree is consistent
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with an X-linked recessive inheritance pattern, as indi-
cated by only female-to-male transmissions of the disease
and by absence of a clinical picture in obligate carrier
females (fig. 1).
The index patient (IV-I) was born at 35 weeks’ ges-
tation and weighed 2300 grams. He showed an axial
hypotonia from his first month of life and was able to
walk without assistance at the age of 2 years. Invol-
untary choreoathetoid movements involving mainly the
upper limbs and the head started at the age of 1 year
and remained throughout the years. At the age of 10
years, his height and cranial circumference were at the
75th percentile and his weight was at the 25th percentile.
His language was severely dysarthric, and his syntax was
rudimentary, making testing for verbal IQ impossible.
Nonverbal IQ was 70 (Leiter scale). A mild spastic hy-
pertonia with hyperflexia was present in the upper and
lower limbs. Gait was discretely wide based, with lumbar
hyperlordosis. Behavioral problems included periods of
aggression and strong agitation. Except for arachno-
dactily, he did not show any dysmorphic features (fig.
2). Lactate, amino acid, and organic acid profiles, very-
long-chain fatty acids, uric acid, copper, ceruloplasmin,
and acanthocytes counts were normal. A search for car-
bohydrate-deficient glycoprotein was negative. No ab-
normalities were noticed on cranial MRI, fundoscopy,
electroretinogram, or positron emission tomography
with (18-F) fluorodeoxyglucose. EEG showed a non-
specific slow dysrhythmia. The patient had a normal
46XY karyotype. His cousin (IV-III) showed choreoath-
etoid movements affecting all four of his limbs and his
head from the age of 3 mo. His involuntary movements
were more severe than those seen in the index patient.
Mental retardation was less severe, affecting primarily
his speech, and he showed no behavioral abnormalities.
No dysmorphic features were noticed. At the age of 12
years, his weight was at the 3d percentile and his cranial
circumference was between the 25th and 50th percen-
tiles. Three uncles (two examined) of the index patient’s
mother showed similar clinical pictures of involuntary
movements in combination with mental retardation.
They were reportedly psychotic, suffering from hallu-
cinations and automutilation. Dysmorphic features were
restricted to arachnodactily (table 1).
DNA and Linkage Analysis
Blood samples were obtained, with informed consent,
from the index patient, his cousin, two affected uncles
(a third affected uncle has died), obligate carriers, two
spouses, and four unaffected males. Genomic DNA was
extracted from lymphocytes by standard procedures.
To cover the whole X chromosome, we selected
markers from two sets of fluorescent-labeled polymor-
phic markers. One set contained fluorescent-labeled
markers described by Reed et al. 1994 (pter-DXS996-
DXS999-DXS451-DMD-DXS538-DXS1068-DXS991-
DXS984-qter); a second set contained microsatellite
markers from The Cooperative Human Linkage Cen-
ter fluorescent-labeled human screening set (Weber ver-
sion 6a) (pter-DXS6807-DXS987-DXS989-DXS6810-
DXS7132-DXS6800-DXS6789-DXS6799-DXS6797-
DXS6804-DXS1001-DXS1193-qter). All polymorphic
markers were genotyped with anABI 377 sequencer (Ap-
plied Biosystems) and analyzed with the aid of GENES-
CAN version 2.1 and GENOTYPER version 2.0 soft-
ware. Additional markers of the Xp11 region were
analyzed by means of standard autoradiographic tech-
niques.
We calculated two-point LOD scores between the dis-
ease and each individual marker, using MLINK of the
linkage package 5.1 (Lathrop and Lalouel 1984). The
frequency of the disease was estimated at .00001, and
equal allele frequencies of .2 were used for each marker.
Results
To define the molecular etiology of the disease in
the family studied, we typed a series of polymorphic
markers along the X chromosome on all persons from
whom blood samples were obtained, except for in-
dividual IV-6 who was not available at the time. Link-
age of the disease with the X chromosome was ex-
cluded except for the region between the markers
DXS451 and DXS6789 (table 2). Additional mark-
ers from within this region (pter-MAOA-DXS1201-
DXS8080-DXS8054-DXS1003-DXS1039-DXS1190-
cen) were typed on all family members, including in-
dividual IV-6. A maximal two-point LOD score of
2.14 at recombination fraction was obtainedv = 0
with markers DXS8080 and DXS8054 (table 2), in-
dicating linkage of the disease with the chromosomal
region Xp11. Haplotype analysis of this chromosomal
region was performed to identify recombination
events and to define a critical disease region. A distal
recombination event occurred between markers
DXS1201 and DXS8080 (identified in individuals IV-
3 and IV-6), and a proximal recombination event oc-
curred between markers DXS1039 and DXS991
(identified in individual IV-7) (fig. 1). Thus, the disease
gene could be positioned in a 20-cM interval between
markers DXS1201 and DXS991 on The Marshfield
Medical Research Foundation X-chromosome map.
In some X-linked conditions, evidence for skewed X
inactivation in carrier females has been described; there-
fore, we analyzed the methylation of HhaI site near the
human androgen-receptor gene in the four female car-
riers of the family. However, no evidence for skewed X
inactivation was found (data not shown).
Fi
gu
re
1
H
ap
lo
ty
pe
an
al
ys
is
on
th
e
pe
di
gr
ee
.
B
la
ck
en
ed
ba
rs
re
pr
es
en
t
th
e
ch
ro
m
os
om
al
re
gi
on
as
so
ci
at
ed
w
it
h
th
e
di
se
as
e.
Reyniers et al.: MR and Choreoathetosis Mapped to Xp11 1409
Figure 2 Frontal (a) and side (b) views of the index patient (IV-
1), showing no characteristic dysmorphic features
Table 1
Clinical Features of the Patients
PHENOTYPE
PATIENT
IV:1 IV:3 II:4 II:5
Cognitive ability:
MR Mild Borderline Mild Mild
Language  /  Unknown Unknown
Movement:
Choreoathetosis 1   5
Spastic hypertonia 0   0
Behavior:
Aggressiveness    
Agitation    
Hallucination    0
Automutilation    0
Dysmorphology:
Arachnodactily 0   0
Discussion
By linkage analysis, we have mapped an X-linked neu-
rological disorder to the short arm of chromosome X in
a 20-cM genetic interval betweenmarkers DXS1201 and
DXS991. Except for mental retardation, patients show
a unique clinical picture, including choreoathetosis and
abnormal behavior. The genetic interval shows overlap
with regions defined for other X-linked neuromuscular
syndromes, including Allan-Herndon-Dudley syndrome
(MIM 309600), Norrie disease (MIM 310600), optic
atrophy 2 (MIM 311050), Wieacker-Wolff syndrome
(MIM 314580), and Hamel BCD (Lubs et al. 1999). It
also encompasses genes or genetic intervals defined for
a metabolic disease (MAOA [MIM 309850]) and for a
number of defined mental retardation syndromes,
namely Aarskog-Scott syndrome (MIM 305400), Ren-
penning syndrome 1 (MIM 309500), Prieto syndrome
(MRXS2; MIM 309610), Sutherland-Haan syndrome
(MRXS3; MIM 309470), Miles-Carpenter syndrome
(MRXS4; MIM 309605), Wilson-Turner syndrome
(MRXS6; MIM 309585), and Ahmad syndrome
(MRXS7) (Lubs et al. 1999). The clinical pictures of
these syndromes and of the patients in our family do
not overlap except for the Sutherland-Haan syndrome
(MRXS3) and Hamel BCD. The Sutherland-Haan syn-
drome is characterized by mental retardation and spas-
ticity as well as by microcephaly, short stature, and small
testes (Sutherland et al. 1988; Martinez et al. 1998).
Hamel BCD is characterized by mental retardation with
spasticity as well as by blindness, convulsions, hypo-
methylation, and early death (Lubs et al. 1999). Since
our patients do not show signs of microcephaly, short
stature, small testes, blindness, convulsions, or early
death, it is unlikely that this new syndrome is allelic to
these described syndromes, and, therefore, we conclude
that the mental retardation/choreoathetosis syndrome in
this family is clinically and genetically unique.
Of the genes mapped to the defined region, the genes
involved in neural signaling and neurotransmitting are
considered potential candidate genes. For instance, point
mutations in cationic channel genes are observed in a
number of autosomal paroxysmal neurological disor-
ders. Mutations in the potassium channel gene KCNA1
cause episodic ataxia with myokymia (MIM 160120)
(Browne et al. 1994); mutations in the sodium channel
gene SCN4A cause hyperkalemic periodic paralysis
(MIM 170500) and paralysis periodica paramyotonia
(MIM 168300) (Rojas et al. 1991); whereas mutations
in the calcium channel genes CACNLIA3 and
CACNA1A cause hypokalemic periodic paralysis (MIM
170400) (Jurkat-Rott et al. 1994) and episodic ataxia,
type 2 (MIM 108500) (Denier et al. 1999), respectively.
Three ion channel genes—a calcium channel gene
(CACNA1F), a chloride channel gene (CLCN5), and a
potassium channel gene (KCND1)—have been mapped
to the candidate region. The first two are not likely can-
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Table 2
Two-Point LOD Scores between the Disease Locus and Markers on the X Chromosome
CYTOGENETIC
LOCATIONa
DISTANCEb
(cM) LOCUS
TWO-POINT LOD SCORE AT v =
0 .01 .05 .1 .2 .3 .4
Xp22.3 4.4 DXS6807  4.26 2.22 1.40 .66 .30 .10
Xp22.33 8.8 DXS996  5.96 3.21 2.08 1.03 .49 .17
Xp22.2 22.4 DXS987  2.80 1.44 .89 .39 .15 .04
Xp22.13 24.2 DXS999  7.06 3.66 2.27 1.01 .42 .11
Xp22.11 37.5 DXS989  3.96 1.94 1.13 .42 .12 .00
Xp22.11 Unknown DXS451c  1.11 .46 .23 .06 .01 .00
Xp21.1 Unknown DMDc .9 .89 .81 .72 .52 .3 .09
Xp11 Unknown DXS538c  .02 .56 .65 .53 .29 .07
Xp11.4 52.6 DXS1068  .32 .87 .97 .86 .59 .27
Xp11.4 63.6 DXS6810 1.15 1.13 1.02 .88 .58 .28 .06
Xp11.4 Unknown MAOAc 1.23 1.21 1.14 1.03 .78 .49 .2
Xp11.4 63.6 DXS1201  .78 .14 .08 .19 .15 .04
Xp11.3 67.9 DXS8080 2.14 2.09 1.93 1.71 1.25 .75 .28
Xp11.3 69.9 DXS8054 2.14 2.09 1.91 1.69 1.21 .71 .25
Xp11.23 72.4 DXS1003 1.83 1.8 1.66 1.48 1.1 .7 .3
Xp11.23 83.3 DXS1039 1.83 1.8 1.66 1.48 1.1 .7 .3
Xp11.21 83.3 DXS1190 .33 .33 .33 .32 .28 .22 .12
Xp11.21 83.3 DXS991  .32 .86 .95 .08 .51 .21
Xq11.11 83.3 DXS7132  7 1.23 1.32 1.15 .81 .39
Xq13.2 93.2 DXS6800 .9 .89 .81 .72 .52 .3 .09
Xq21.33 103.6 DXS6789  1.97 .66 .18 .16 .22 .15
Xq21.33 107.4 DXS6799  3.37 1.39 .64 .06 .12 .12
Xq23 112.9 DXS6797  3.37 1.39 .64 .06 .12 .12
Xq23 116.2 DXS6804  4.26 2.22 1.39 .64 .29 .10
Xq24 130.4 DXS1001  4.85 2.77 1.89 1.04 .56 .23
Xq26.3 150.2 DXS984  7.36 3.95 2.55 1.26 .61 .23
Xq28 175.3 DXS1193  4.85 2.77 1.90 1.05 .58 .25
NOTE.—The excluded regions are boxed; the critical region is underlined.
a Inferred cytogenetic location, according to The Genetic Location Database..
b From locus to pter, according to The Marshfield Medical Research Foundation genetic maps.
c Positioned according to Reed et al. (1994).
didate genes for the syndromic features of our family,
since loss of function mutations in CACNA1F cause
night blindness, congenital stationary, type 2 (MIM
300071) (Strom et al. 1998), and the expression level of
this gene in the brain is low (Fisher et al. 1997). Mu-
tations in the chloride channel gene CLCN5 are found
in different renal tubular disorders complicated by ne-
phrolithiasis (Lloyd et al. 1996). The KCND1 gene is a
more likely candidate. It encodes a Shal-type potassium
channel gene, and the transmembane domain S7 of this
gene shows high homology with the corresponding S6
transmebrane domain of the Shaker-type potassium
channel KCNA1 mutated in episodic ataxia/myokymia
(Browne et al. 1994).
Two presynaptic proteins potentially involved in neu-
rotransmitter release are mapped to the region of inter-
est, synapsin (Yang-Feng et al. 1986) and synaptophysin
(Ozcelik et al. 1990). Synapsin I has a possible role in
regulation of axonogenesis and synaptogenesis (Li et al.
1995), whereas synaptophysin is one of the major in-
tegral membrane proteins of the small electron-trans-
lucent transmitter-containing vesicles (Ozcelik et al.
1990). No disease has yet been associated with muta-
tions in one of these genes. However, gene-deficient mice
lacking either synapsin (Li et al. 1995) or synaptophysin
(Eshkind and Leube 1995) have been constructed and
studied, and no mention of choreoathetosis or spasticity
in either of the two knockout mice was made. This does
not formally exclude these two genes as candidate genes:
knockout mice deficient in HPRT synthesis, a mouse
model for Lesch-Nyhan syndrome, do not show any ev-
idence of the symptoms characteristic for the human
disease, including choreoathetosis, spasticity, or self-mu-
tilation (Engle et al. 1996).
Other potential candidate genes in the region, such as
the monoamine oxidases A (MAOA) and B (MAOB),
involved in the degradation of biogenic amines serotonin
and norepinephrine, and phenylethylamine and dopa-
mine, respectively, map outside the candidate region.
Recently, a novel orphan G protein–coupled receptor
gene (GPR34), with high expression in the brain, has
been discovered and assigned to the candidate region
(Xp11.3) as well as to a nonhomologous chromosome
(4p12) by fluorescence in situ hybridization (Marchese
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et al. 1999). G protein–coupled receptors (GPCRs) me-
diate signals to the interior of the cell by activation of
G proteins. These G proteins, in turn, activate a number
of effector proteins and possibly regulate Ras-like
GTPase pathways (Bokoch 1996). It has been demon-
strated that there is an association between cognitive
impairment and a defective signaling pathway depending
on Ras-like GTPase in three different types of nonsyn-
dromic mental retardation (Bienvenu et al. 1998; Billuart
et al. 1998; D’Adamo et al. 1998), and it has been pos-
tulated that GPCRs play a role in behavior and neu-
ropsychiatric disorders (Blum and Noble 1997). There-
fore, mutations in GPR34 (Xp11.3) could theoretically
explain the phenotype of the patients in our family.
In conclusion, we have defined a thus far unknown
neurological syndrome that maps to Xp11. The region
contains several interesting candidate genes involved in
neuronal signaling.Mutation analysis of these genesmay
in the future elucidate the molecular defect of these pa-
tients. In addition, knowledge of the defective gene may
help us to understand more about cognitive function and
movement disorders.
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